Paysign, Inc. (PAYS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2024. Paysign, Inc. is a vertically integrated provider of prepaid card products and processing services, focusing on corporate, consumer, and government applications. Key verticals include the plasma industry (donor compensation) and the pharmaceutical industry (patient affordability programs). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $14.33 million | $11.04 million | $27.52 million | $21.18 million |
| Gross Profit | $7.59 million | $5.62 million | $14.53 million | $10.66 million |
| Gross Margin | 52.9% | 50.9% | 52.8% | 50.3% |
| Net Income (Loss) | $0.70 million | ($0.10 million) | $1.01 million | ($0.26 million) |
| EPS (Diluted) | $0.01 | ($0.00) | $0.02 | ($0.01) |
| Operating Cash Flow (YTD) | $28.80 million (2024) vs $0.15 million (2023) | |||
| Cash & Restricted Cash | $133.53 million (as of June 30, 2024) | |||
| Customer Card Funding (Liability) | $102.08 million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 29.8% quarter-over-quarter and 29.9% year-to-date.
- Pharma Industry: Revenue surged 266.8% in Q2 and 284.0% YTD, driven by the launch of 30 net new patient affordability programs.
- Plasma Industry: Revenue grew 12.6% in Q2 and 11.7% YTD, attributed to adding 35 new plasma centers and increased donation volumes.
- Profitability: The company returned to profitability, reporting net income of $0.70 million in Q2 2024 compared to a net loss of $0.10 million in Q2 2023. Operating income improved from a loss of $0.65 million to a profit of $0.13 million.
- Expense Management: Operating expenses increased 19.1% in Q2, primarily due to higher compensation costs ($1.3M increase) and technology investments ($0.37M increase), partially offset by a decrease in stock-based compensation.
- Liquidity: Operating cash flow improved dramatically to $28.8 million YTD 2024 from $0.15 million YTD 2023, largely due to timing differences in accounts receivable and payables related to the pharma business.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue investing in technology, sales, marketing, and cybersecurity. They believe current cash reserves ($31.3 million unrestricted) and forecasted cash flows are sufficient to sustain operations through Q2 2026 without raising new capital.
- Legal Proceedings:
- Securities Class Action: A settlement of $3.75 million was approved by the court in April 2024. The full amount is covered by the company's directors-and-officers insurance policy.
- Derivative Actions: Four stockholder derivative actions remain pending. The company intends to file motions to dismiss if these do not settle. No meaningful estimate of damages can be provided at this time.
- Risk Factors: The company notes concentration risk in accounts receivable, with three pharma customers representing 48% of the total receivable balance as of June 30, 2024. Additionally, a significant portion of cash is held in one financial institution, exceeding FDIC limits, though a deposit swapping program is in place to mitigate this risk.
Investor Verification Checklist
- Pharma Concentration: Verify the stability of the top three pharma customers, which collectively hold nearly half of the accounts receivable balance.
- Settlement Finality: Confirm the final disbursement of the $3.75 million class action settlement and ensure no further liability remains.
- Derivative Litigation: Monitor the status of the four pending stockholder derivative actions for potential settlement terms or dismissal rulings.
- Cash Flow Sustainability: Assess the sustainability of the improved operating cash flow, specifically the timing of passthrough claim reimbursements in the pharma business.
- Banking Risk: Review the effectiveness of the "deposit swapping" program in mitigating the risk of uninsured cash deposits exceeding federal limits.